Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method of ~~assessing~~ screening ~~whether~~ a human subject ~~is susceptible~~ for susceptibility to type 2 diabetes comprising the steps of:

(a) determining the SorCS1 cDNA sequence of ~~that~~ the subject;

(b) deducing the amino acid sequence encoded by the sequenced cDNA; ~~and~~

(c) comparing the deduced SorCS1 amino acid sequence with a reference sequence, SEQ ID NO:4~~, wherein~~; and

(d) screening for a difference in the deduced amino acid sequence relative to reference SEQ ID NO:4 ~~indicates that the subject is susceptible to developing type 2 diabetes~~, ~~wherein~~ the difference consisting of ~~is~~ a change from a threonine to a isoleucine ~~substitution~~ at ~~amino acid~~ position 52 of the human SorCS1 amino acid sequence, and wherein the difference is associated with susceptibility to type 2 diabetes ~~of the SorCS1 amino acid sequence~~.

2. (Currently amended) A method of ~~assessing~~ screening ~~whether~~ a human subject ~~is susceptible~~ for susceptibility to type 2 diabetes comprising the steps of:

(a) determining the SorCS1 cDNA sequence of the subject ~~in the SorCS1~~; ~~and~~

(b) comparing the determined SorCS1 cDNA sequence with a reference sequence, SEQ ID NO:3;~~,~~ and

(c) screening for a difference at nucleotide position 163 in the determined sequence relative to reference SEQ ID NO:3, the difference consisting of a change from a cytosine to a thymine at nucleotide position 163, wherein the nucleotide difference at position 163 of the human SorCS1 cDNA sequence is associated with susceptibility to type 2 diabetes ~~wherein a difference in the determined cDNA sequence relative to SEQ ID NO:3 indicates that the subject is susceptible to developing type 2 diabetes, wherein the difference is a cytosine to a thymine substitution at nucleotide position 172 of the SorCS1 cDNA sequence~~

3. -12. (cancelled).